CytomX Therapeutics (NASDAQ: CTMX) net income
CytomX Therapeutics reported a net loss of $17.4m for fiscal 2025; in fiscal 2024 it reported a net profit of $31.9m.
CytomX Therapeutics's best year of the last 10 was fiscal 2024. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin |
|---|---|---|---|
| 2025 | −$17.4m | −154.5% | −22.8% |
| 2024 | $31.9m | — | 23.1% |
| 2023 | −$0.6m | — | −0.6% |
| 2022 | −$99.3m | — | −186.8% |
| 2021 | −$115.9m | — | −310.5% |
| 2020 | −$64.8m | — | −94.7% |
| 2019 | −$132.8m | — | −493.7% |
| 2018 | −$84.6m | — | −142.2% |
| 2017 | −$43.1m | — | −60.2% |
| 2016 | −$58.9m | — | −391.5% |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
CytomX Therapeutics net income compared with its sector
By net income for its latest fiscal year, CytomX Therapeutics ranks 203rd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of CytomX Therapeutics, −22.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 201st | Palisade Bio | −$16.8m | — |
| 202nd | Alpha Teknova | −$17.3m | −42.6% |
| 203rd | CytomX Therapeutics | −$17.4m | −22.8% |
| 204th | Ovid Therapeutics | −$17.4m | −240.1% |
| 205th | RadNet | −$18.7m | −0.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of CytomX Therapeutics
- How much did CytomX Therapeutics earn in fiscal 2025?
- CytomX Therapeutics reported a net loss of $17.4m for fiscal 2025. In fiscal 2024 it reported a net profit of $31.9m.
- What was the most profitable year for CytomX Therapeutics?
- Of its last 10 fiscal years, fiscal 2024, with $31.9m.
- Where does CytomX Therapeutics rank in its sector by net income?
- It ranks 203rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for CytomX Therapeutics come from?
- From the annual report (Form 10-K) that CytomX Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that CytomX Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on CytomX Therapeutics: the CytomX Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.